GASTRICHIP TRIAL. D2 resection and HIPEC (Hyperthermic IntraPeritoneal Chemoperfusion) in locally advanced gastric carcinoma. A randomized and multicentric phase III study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516358-23-00

Acronym

2012-761

Enrollment

367

Registered

2024-08-26

Start date

2013-06-24

Completion date

Unknown

Last updated

2025-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric adenocarcinoma

Brief summary

Overall survival

Detailed description

Recurrence-free survivals (peritoneal recurrence, locoregional recurrence, metastatic recurrence, site of recurrence ), Treatment-related toxicity, Treatment-related mortality, Treatment related morbidity, Quality of life

Interventions

DRUGCALCIUM LEVOFOLINATE

DRUGFLUOROURACIL

DRUGOXALIPLATIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Recurrence-free survivals (peritoneal recurrence, locoregional recurrence, metastatic recurrence, site of recurrence ), Treatment-related toxicity, Treatment-related mortality, Treatment related morbidity, Quality of life	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026